X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.
Lead Product(s): SDC-1801
Therapeutic Area: Dermatology Product Name: SDC-1801
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2023
Details:
SDC-1801 is a TYK2/JAK1 inhibitor being developed as a potential new therapeutic for a range of autoimmune diseases with an initial focus on psoriasis, an autoimmune condition affecting the skin.
Lead Product(s): SDC-1801
Therapeutic Area: Dermatology Product Name: SDC-1801
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
The United States Patent and Trademark Office has now formally approved its patent application (US Patent Application no. 16/351,620), in respect of an invention associated with Sareum’s proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme.
Lead Product(s): SDC-1802
Therapeutic Area: Immunology Product Name: SDC-1802
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
Sareum’s received £174,000 in grant funding to investigate the therapeutic potential of SDC-1801, its selective, small molecule TYK2/JAK1 kinase inhibitor, in severe-phase Covid-19.
Lead Product(s): SDC-1801
Therapeutic Area: Infections and Infectious Diseases Product Name: SDC-1801
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: UKRI
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding December 03, 2020
Details:
The patent will protect the SDC-1802 molecule and pharmaceutical preparations thereof. Subject to certain formalities being completed, the Company expects that the patent will be granted within three months.
Lead Product(s): SDC-1802
Therapeutic Area: Oncology Product Name: SDC-1802
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The authors concluded that an approach using selective TYK2/JAK1 inhibitors may lead to the development of a therapy for lupus that does not involve the harmful side effects of systemic immune system suppression and may benefit numerous lupus patients in need of new options.
Lead Product(s): SDC-1802
Therapeutic Area: Immunology Product Name: SDC-1802
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
